Morgan Stanley Maintains Overweight on Dentsply Sirona, Lowers Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Erin Wright has maintained an Overweight rating on Dentsply Sirona (NASDAQ:XRAY) but lowered the price target from $47 to $43.

October 20, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Dentsply Sirona but lowered the price target from $47 to $43.
The news is directly about Dentsply Sirona and is likely to impact its stock price. While the Overweight rating suggests that Morgan Stanley expects the stock to outperform, the lowering of the price target may create some negative sentiment among investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100